Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment

With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic o...

Descripción completa

Detalles Bibliográficos
Autor principal: Reiff, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare Communications 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873121/
https://www.ncbi.nlm.nih.gov/pubmed/24392296
http://dx.doi.org/10.1007/s13554-012-0001-6
_version_ 1782297061031411712
author Reiff, Andreas
author_facet Reiff, Andreas
author_sort Reiff, Andreas
collection PubMed
description With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic options for sJIA, to summarize the history of the clinical trials with tocilizumab, and to discuss its role in the treatment of sJIA.
format Online
Article
Text
id pubmed-3873121
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Healthcare Communications
record_format MEDLINE/PubMed
spelling pubmed-38731212014-01-02 Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment Reiff, Andreas Biol Ther Review With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic options for sJIA, to summarize the history of the clinical trials with tocilizumab, and to discuss its role in the treatment of sJIA. Springer Healthcare Communications 2012-02-01 /pmc/articles/PMC3873121/ /pubmed/24392296 http://dx.doi.org/10.1007/s13554-012-0001-6 Text en © Springer Healthcare 2012 https://creativecommons.org/licenses/by-nc/4.0/ Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Review
Reiff, Andreas
Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
title Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
title_full Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
title_fullStr Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
title_full_unstemmed Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
title_short Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
title_sort treatment of systemic juvenile idiopathic arthritis with tocilizumab - the role of anti-interleukin-6 therapy after a decade of treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3873121/
https://www.ncbi.nlm.nih.gov/pubmed/24392296
http://dx.doi.org/10.1007/s13554-012-0001-6
work_keys_str_mv AT reiffandreas treatmentofsystemicjuvenileidiopathicarthritiswithtocilizumabtheroleofantiinterleukin6therapyafteradecadeoftreatment

Ejemplares similares